Swiss - Delayed Quote • CHF
Roche Holding AG (RO.SW)
At close: April 22 at 5:31 PM GMT+2
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 1 |
| Avg. Estimate | 0 | 0 | 17.7 | 19.92 |
| Low Estimate | 0 | 0 | 17.7 | 19.92 |
| High Estimate | 0 | 0 | 17.7 | 19.92 |
| Year Ago EPS | -- | -- | 18.57 | 17.7 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | -- | 1 | 1 |
| Avg. Estimate | 60.38B | -- | 60.38B | 64.97B |
| Low Estimate | 60.38B | -- | 60.38B | 64.97B |
| High Estimate | 60.38B | -- | 60.38B | 64.97B |
| Year Ago Sales | 58.72B | -- | 58.72B | 60.38B |
| Sales Growth (year/est) | 2.80% | -- | 2.80% | 7.60% |
Earnings History
| CURRENCY IN USD | ||||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -- |
| EPS Actual | -- | -- | -- | -- |
| Difference | -- | -- | -- | -- |
| Surprise % | -- | -- | -- | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 17.7 | 19.92 |
| 7 Days Ago | 0 | 0 | 17.7 | 19.92 |
| 30 Days Ago | 0 | 0 | 17.07 | 19.33 |
| 60 Days Ago | 0 | 0 | 17.05 | 19.05 |
| 90 Days Ago | 0 | 0 | 17.5 | 19.16 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | RO.SW | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 0.20% |
| Next Qtr. | -- | -- | -- | 9.40% |
| Current Year | -4.70% | -- | -- | 4.40% |
| Next Year | 12.50% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -- | -- | -- | 11.07% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
No Fair Value available for this ticker
Related Tickers
NOVN.SW Novartis AG
87.36
+2.14%
ABBV.BA AbbVie Inc.
17,816.50
+0.18%
GLAXO.BO GlaxoSmithKline Pharmaceuticals Limited
1,948.10
+4.24%
SNW.DE Sanofi
88.11
+1.68%
AMG.F Amgen Inc.
256.90
+3.17%
1BAYN.MI Bayer Aktiengesellschaft
27.00
+2.97%
AMG.DE Amgen Inc.
254.35
+2.05%
SAN.PA Sanofi
88.17
+1.47%
BAYN.DE Bayer Aktiengesellschaft
27.32
+3.76%
AZN.L AstraZeneca PLC
11,250.00
+2.78%